Global Epinephrine Auto-Injectors Market Growth 2025-2031

Global Epinephrine Auto-Injectors Market Growth 2025-2031

The global Epinephrine Auto-Injectors market size is predicted to grow from US$ 1393 million in 2025 to US$ 1904 million in 2031; it is expected to grow at a CAGR of 5.3% from 2025 to 2031.

Epinephrine auto-injector is an emergency injection ("shot") of epinephrine. It is used against life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure. This medication is used in emergencies to treat very serious allergic reactions to insect stings/bites, foods, drugs, or other substances. Epinephrine acts quickly to improve breathing, stimulate the heart, raise a dropping blood pressure, reverse hives, and reduce swelling of the face, lips, and throat.

Global core Epinephrine Auto-Injectors manufacturers include Viatris, Teva Pharmaceutica etc. The top 1 company hold a share about 42%. North America is the largest market, with a share about 75%, followed by Europe which shares about 20%. In terms of product, 0.3 mg is the largest segment, with a share about 80%. And in terms of application, the largest end user is over 12 years patients.

LP Information, Inc. (LPI) ' newest research report, the “Epinephrine Auto-Injectors Industry Forecast” looks at past sales and reviews total world Epinephrine Auto-Injectors sales in 2024, providing a comprehensive analysis by region and market sector of projected Epinephrine Auto-Injectors sales for 2025 through 2031. With Epinephrine Auto-Injectors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Epinephrine Auto-Injectors industry.

This Insight Report provides a comprehensive analysis of the global Epinephrine Auto-Injectors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Epinephrine Auto-Injectors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Epinephrine Auto-Injectors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Epinephrine Auto-Injectors and breaks down the forecast by Type, by End User, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Epinephrine Auto-Injectors.

This report presents a comprehensive overview, market shares, and growth opportunities of Epinephrine Auto-Injectors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
0.3 mg
0.15 mg
0.5 mg
0.1 mg

Segmentation by End User:
Under 6 Years Patients
6 to 12 Years Patients
Over 12 Years Patients

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Viatris
Teva Pharmaceutica
ALK Abello
Amneal Pharmaceuticals
Kaléo
Bioprojet Pharma
Bausch Health
Novartis Sandoz

Key Questions Addressed in this Report

What is the 10-year outlook for the global Epinephrine Auto-Injectors market?

What factors are driving Epinephrine Auto-Injectors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Epinephrine Auto-Injectors market opportunities vary by end market size?

How does Epinephrine Auto-Injectors break out by Type, by End User?

Please note: The report will take approximately 2 business days to prepare and deliver.